Legend Biotech Net Income Over Time
| LEGN Stock | USD 17.59 0.01 0.06% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Legend Biotech Performance and Legend Biotech Correlation. Will Biotechnology sector continue expanding? Could Legend diversify its offerings? Factors like these will boost the valuation of Legend Biotech. Expected growth trajectory for Legend significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Legend Biotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.28) | Revenue Per Share | Quarterly Revenue Growth 0.7 | Return On Assets | Return On Equity |
Investors evaluate Legend Biotech Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Legend Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Legend Biotech's market price to deviate significantly from intrinsic value.
Understanding that Legend Biotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Legend Biotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Legend Biotech's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Legend Biotech Corp and related stocks such as Disc Medicine, Zai Lab, and Ascentage Pharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IRON | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (40.8 M) | (36 M) | (46.1 M) | (76.4 M) | (109.4 M) | (98.4 M) | (103.3 M) |
| ZLAB | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (37.5 M) | (50.4 M) | (139.1 M) | (183.4 M) | (268.9 M) | (704.5 M) | (443.3 M) | (334.6 M) | (257.1 M) | (231.4 M) | (243 M) |
| AAPG | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (107.8 M) | (118.5 M) | (345.3 M) | (1.5 B) | (677.6 M) | (782.4 M) | (882.9 M) | (925.6 M) | (405.4 M) | (364.9 M) | (383.1 M) |
| TARS | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (4.7 M) | (26.8 M) | (13.8 M) | (62.1 M) | (135.9 M) | (115.6 M) | (104 M) | (98.8 M) |
| ADPT | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (42.8 M) | (46.4 M) | (68.6 M) | (146.2 M) | (207.3 M) | (200.2 M) | (225.2 M) | (159.5 M) | (59.5 M) | (62.5 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (63.8 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
| XENE | (12 M) | (12 M) | (4.3 M) | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (34.5 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (182.4 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| IDYA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (34.3 M) | (38.4 M) | (32.3 M) | (47.5 M) | (54.8 M) | (113 M) | (274.5 M) | (247 M) | (234.7 M) |
Legend Biotech Corp and related stocks such as Disc Medicine, Zai Lab, and Ascentage Pharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Legend Biotech Corp financial statement analysis. It represents the amount of money remaining after all of Legend Biotech Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Legend Biotech Corp | LEGN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2101 Cottontail Lane, |
| Exchange | NASDAQ Exchange |
USD 17.59
Check out Legend Biotech Performance and Legend Biotech Correlation. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Legend Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.